

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥(煙台)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

VOLUNTARY ANNOUNCEMENT

Receipt of US\$650 Million Upfront Payment from AbbVie under the Exclusive License Agreement for RC148

This announcement is made by RemeGen Co., Ltd.*榮昌生物製藥(煙台)股份有限公司(the “**Company**”) on a voluntary basis.

Reference is made to the announcement of the Company dated January 12, 2026 in relation to the entering of an exclusive license agreement with AbbVie Inc. (hereinafter referred to as “**AbbVie**”).

On January 12, 2026, the Company entered into an exclusive license agreement with AbbVie for RC148, which became effective on March 10, 2026. Pursuant to the agreement, AbbVie would obtain exclusive rights to develop, manufacture and commercialize RC148 outside Greater China. In consideration, the Company would receive an US\$650 million upfront payment and is eligible to receive additional development, regulatory and commercial milestone payments of up to US\$4.95 billion, as well as tiered double-digit royalty payments based on net sales of RC148 outside Greater China.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company has received the US\$650 million upfront payment from AbbVie (through its holding company) under the exclusive license agreement for RC148, a novel PD-1/VEGF targeting bispecific antibody drug independently developed by the Company. The collaboration between the two parties is progressing smoothly.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive director

Yantai, The People's Republic of China
April 15, 2026

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Wen Qingkai and Mr. Lin Jian as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Mr. Hao Xianjing, Mr. Chen Yunjin and Mr. Huang Guobin as the independent non-executive directors.

* For identification purposes only